Guideline
ACC/AHA multisociety dyslipidaemia guideline (2026)
Status Current
The 2026 United States multisociety dyslipidaemia guideline. Like its European counterpart it carries no recommendation for CETP inhibition; it is included because it defines the American treatment thresholds against which any future approval will be judged.
The exact wording on emerging agents still needs to be read in full and quoted precisely here; see the open items in the site documentation. Until then this entry is a pointer to the document, not a summary of its position on this class.
Page updated 18 August 2026.